303 related articles for article (PubMed ID: 34566643)
1. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
Li S; Li J; Peng L; Li Y; Wan X
Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
[No Abstract] [Full Text] [Related]
2. Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.
Li S; Li J; Peng L; Li Y; Wan X
Front Pharmacol; 2021; 12():736860. PubMed ID: 34966275
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
5. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Six Immunotherapy-Based Regimens and Sunitinib in Metastatic Renal Cell Carcinoma: A Public Payer Perspective.
Yoo M; Nelson RE; Cutshall Z; Dougherty M; Kohli M
JCO Oncol Pract; 2023 Mar; 19(3):e449-e456. PubMed ID: 36599117
[TBL] [Abstract][Full Text] [Related]
7. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
[TBL] [Abstract][Full Text] [Related]
8. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Suárez C; Bourlon MT; Barata PC; Gulati S; Huo S; Ejzykowicz F; Blum SI; Del Tejo V; Hamilton M; May JR; Du EX; Wu A; Kral P; Ivanescu C; Chin A; Betts KA; Lee CH; Choueiri TK; Cella D; Porta C
Eur Urol Oncol; 2023 Jun; 6(3):339-348. PubMed ID: 36842942
[TBL] [Abstract][Full Text] [Related]
9. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
11. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Treatment Sequences in Advanced Renal Cell Carcinoma.
Mason NT; Joshi VB; Adashek JJ; Kim Y; Shah SS; Schneider AM; Chadha J; Jim HSL; Byrne MM; Gilbert SM; Manley BJ; Spiess PE; Chahoud J
Eur Urol Oncol; 2023 Jun; 6(3):331-338. PubMed ID: 36797084
[TBL] [Abstract][Full Text] [Related]
14. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.
Su Y; Fu J; Du J; Wu B
Ther Adv Med Oncol; 2020; 12():1758835920950199. PubMed ID: 32874210
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma.
Shay R; Nicklawsky A; Gao D; Lam ET
Clin Genitourin Cancer; 2021 Aug; 19(4):370-370.e7. PubMed ID: 33674224
[TBL] [Abstract][Full Text] [Related]
17. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
[TBL] [Abstract][Full Text] [Related]
18. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Peng L
Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
[TBL] [Abstract][Full Text] [Related]
20. A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.
Lu P; Liang W; Li J; Hong Y; Chen Z; Liu T; Dong P; Huang H; Zhang T; Jiang J
Front Pharmacol; 2020; 11():619. PubMed ID: 32457618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]